These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 39008470)
41. Expression of the embryonic morphogen Nodal in cutaneous melanocytic lesions. Yu L; Harms PW; Pouryazdanparast P; Kim DS; Ma L; Fullen DR Mod Pathol; 2010 Sep; 23(9):1209-14. PubMed ID: 20495543 [TBL] [Abstract][Full Text] [Related]
42. The usefulness of c-Kit in the immunohistochemical assessment of melanocytic lesions. Pilloni L; Bianco P; Difelice E; Cabras S; Castellanos ME; Atzori L; Ferreli C; Mulas P; Nemolato S; Faa G Eur J Histochem; 2011 Jun; 55(2):e20. PubMed ID: 22193299 [TBL] [Abstract][Full Text] [Related]
44. PRAME expression in genital melanocytic lesions - Potential diagnostic pitfall of intermediate expression in atypical genital nevi. Ng JKM; Choi PCL; Chow C; Li JJX; To KF Pathol Res Pract; 2024 Aug; 260():155404. PubMed ID: 38878667 [TBL] [Abstract][Full Text] [Related]
45. p16 and p21WAF1 protein expression in melanocytic tumors by immunohistochemistry. Sparrow LE; Eldon MJ; English DR; Heenan PJ Am J Dermatopathol; 1998 Jun; 20(3):255-61. PubMed ID: 9650698 [TBL] [Abstract][Full Text] [Related]
46. Primary malignant melanoma of the oesophagus: a clinical and pathological study with emphasis on the immunophenotype of the tumours for melanocyte differentiation markers and cancer/testis antigens. Lohmann CM; Hwu WJ; Iversen K; Jungbluth AA; Busam KJ Melanoma Res; 2003 Dec; 13(6):595-601. PubMed ID: 14646623 [TBL] [Abstract][Full Text] [Related]
47. Expression of the tumor suppressor gene product p16INK4 in benign and malignant melanocytic lesions. Keller-Melchior R; Schmidt R; Piepkorn M J Invest Dermatol; 1998 Jun; 110(6):932-8. PubMed ID: 9620301 [TBL] [Abstract][Full Text] [Related]
48. Canine melanocytes: Immunohistochemical expression of melanocytic markers in different somatic areas. Porcellato I; Orlandi M; Lo Giudice A; Sforna M; Mechelli L; Brachelente C Vet Dermatol; 2023 Aug; 34(4):284-297. PubMed ID: 36808650 [TBL] [Abstract][Full Text] [Related]
49. PNL2, a new monoclonal antibody directed against a fixative-resistant melanocyte antigen. Rochaix P; Lacroix-Triki M; Lamant L; Pichereaux C; Valmary S; Puente E; Al Saati T; Monsarrat B; Susini C; Buscail L; Delsol G; Voigt JJ Mod Pathol; 2003 May; 16(5):481-90. PubMed ID: 12748255 [TBL] [Abstract][Full Text] [Related]
50. High expression of immunotherapy candidate proteins gp100, MART-1, tyrosinase and TRP-1 in uveal melanoma. de Vries TJ; Trancikova D; Ruiter DJ; van Muijen GN Br J Cancer; 1998 Nov; 78(9):1156-61. PubMed ID: 9820172 [TBL] [Abstract][Full Text] [Related]
51. Immunohistochemical and reverse transcription-polymerase chain reaction expression analysis of tyrosinase and microphthalmia-associated transcription factor in angiomyolipomas. Jungbluth AA; King R; Fisher DE; Iversen K; Coplan K; Kolb D; Williamson B; Chen YT; Stockert E; Old LJ; Busam KJ Appl Immunohistochem Mol Morphol; 2001 Mar; 9(1):29-34. PubMed ID: 11277411 [TBL] [Abstract][Full Text] [Related]
52. Preferentially Expressed Antigen in Melanoma Immunostaining in a Series of Melanocytic Neoplasms. Googe PB; Flanigan KL; Miedema JR Am J Dermatopathol; 2021 Nov; 43(11):794-800. PubMed ID: 33989214 [TBL] [Abstract][Full Text] [Related]
53. Aberrant intermediate filament and synaptophysin expression is a frequent event in malignant melanoma: an immunohistochemical study of 73 cases. Romano RC; Carter JM; Folpe AL Mod Pathol; 2015 Aug; 28(8):1033-42. PubMed ID: 26022451 [TBL] [Abstract][Full Text] [Related]